Biohaven Ltd (BHVN) NPV

Sell:$19.26Buy:$20.09$3.56 (15.21%)

Prices delayed by at least 15 minutes
Sell:$19.26
Buy:$20.09
Change:$3.56 (15.21%)
Prices delayed by at least 15 minutes
Sell:$19.26
Buy:$20.09
Change:$3.56 (15.21%)
Prices delayed by at least 15 minutes

Company Information

About this company

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Key people

Vlad Coric
Chairman of the Board, Chief Executive Officer
Matthew Buten
Chief Financial Officer
Kimberly Gentile
Senior Vice President of Clinical Operations
Bruce Car
Chief Scientific Officer
Michael Thomas Heffernan
Lead Independent Director
Kishen Mehta
Director
Irina Antonijevic
Independent Director
Gregory Hugh Bailey
Independent Director
John W. Childs
Independent Director
Click to see more

Key facts

  • EPIC
    BHVN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    VGG1110E1079
  • Market cap
    $2.19bn
  • Employees
    256
  • Shares in issue
    102.06m
  • Exchange
    New York Stock Exchange
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.